Products
Pradusinstobart Biosimilar Monoclonal Antibody (PD-1) for Research
Cat No.: GMP-Bios-INN-1345
Anti-PDCD1/CD279/PD1 therapeutic antibody (Pre-made Pradusinstobart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Pradusinstobart (development code LVGN-3616) is a humanized monoclonal antibody targeting PD-1 (PDCD1). It is developed by MD Anderson Cancer Center and Lyvgen Biopharma for Gastric cancers, Head and neck cancers, Esophageal cancers et al. in Phase I development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1345-1mg | 1mg | 3090 |
| GMP-Bios-INN-1345-10mg | 10mg | |
| GMP-Bios-INN-1345-100mg | 100mg | |
| GMP-Bios-INN-1345-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Pradusinstobart biosimilar, Whole mAb, Anti-PDCD1/CD279/PD1 Antibody: Anti-PD-1/CD279/PDCD1/Programmed cell death protein 1 therapeutic antibody |
| INN Name | Pradusinstobart |
| Target | PDCD1/CD279/PD1 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2022 |
| Year Recommended | 2023 |
| Companies | MD Anderson Cancer Center;Lyvgen Biopharma |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Gastric cancers;Head and neck cancers;Esophageal cancers;Hepatocellular cancers;Metastatic cancers |
| Production | na |
| Development Tech | na |
